Several attempts to block Gal-3 expression with lentiviral shRNA or its function with a carbohydrate-derived competitive inhibitor have so far yielded encouraging results in experimental in vitro models of AML. The gene discussed is LGALS3; the disease is acute myeloid leukemia.